FLONASE SENSIMIST ALLERGY RELIEF
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FLONASE SENSIMIST ALLERGY RELIEF (FLONASE SENSIMIST ALLERGY RELIEF).
Fluticasone propionate is a corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of pro-inflammatory cytokines, suppression of inflammatory cell migration, and reduction of mucosal edema.
| Metabolism | Hepatic via CYP3A4 to inactive metabolites |
| Excretion | Fluticasone propionate is eliminated primarily via hepatic metabolism and subsequent renal excretion. Following oral administration, approximately 87-90% of the dose is excreted in feces as metabolites, with less than 5% excreted unchanged in urine. After intranasal administration, the swallowed portion undergoes first-pass metabolism, and systemic absorption is minimal; the eliminated fraction follows the same pattern. |
| Half-life | The terminal elimination half-life of fluticasone propionate after intravenous administration is approximately 7.8 hours. After intranasal administration, due to slow absorption from the nasal mucosa and extensive first-pass metabolism, the apparent half-life is prolonged, ranging from 10 to 15 hours, reflecting the flip-flop pharmacokinetics. |
| Protein binding | Fluticasone propionate is approximately 91% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | The volume of distribution at steady state (Vdss) is approximately 4.2 L/kg, indicating extensive tissue distribution. This large Vd reflects high lipophilicity and tissue binding. |
| Bioavailability | Intranasal bioavailability is less than 2% due to low systemic absorption and extensive first-pass metabolism of the swallowed portion. Oral bioavailability is negligible (<1%) due to first-pass metabolism. |
| Onset of Action | Onset of action for relief of seasonal allergic rhinitis symptoms occurs within 12 hours after the first intranasal dose, with clinically significant improvement seen in some patients by 12 hours and maximum benefit observed after several days of regular use. |
| Duration of Action | Duration of action is 24 hours, allowing once-daily dosing (200 mcg per day). Symptom control is maintained with regular daily use; however, individual response may vary. |
110 mcg (2 sprays) intranasally once daily; after 1 week, may reduce to 55 mcg (1 spray) per nostril once daily for maintenance.
| Dosage form | SPRAY, METERED |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Children 2-11 years: 55 mcg (1 spray) per nostril intranasally once daily. Children 12 years and older: same as adult dosing. |
| Geriatric use | No dose adjustment required; use with caution in elderly due to potential increased sensitivity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for FLONASE SENSIMIST ALLERGY RELIEF (FLONASE SENSIMIST ALLERGY RELIEF).
| Breastfeeding | Fluticasone propionate is excreted in human milk in unknown amounts. M/P ratio not established. Use caution due to potential for growth suppression or adrenal effects in the nursing infant. Recommend lowest effective dose. |
| Teratogenic Risk | FDA Pregnancy Category C. Inhaled corticosteroid fluticasone propionate has not demonstrated significant teratogenicity in animal studies at doses exceeding clinical exposure. First trimester: No increased risk of major congenital malformations from population-based studies. Second and third trimesters: Risk of fetal growth restriction with prolonged high-dose use. Monitor for adrenal suppression in neonates if maternal treatment continues to term. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to fluticasone propionate or any excipients","Untreated localized nasal infections"]
| Precautions | ["May cause epistaxis, nasal ulceration, or nasal septal perforation","Monitor for signs of hypercorticism with prolonged use","Risk of immunosuppression and increased susceptibility to infections","Use caution in patients with tuberculosis or untreated fungal/bacterial/viral infections","May delay wound healing after nasal surgery or trauma"] |
Loading safety data…
| Fetal Monitoring | Monitor fetal growth via ultrasound if long-term treatment. Maternal assessment for adrenal suppression (rare). Neonatal observation for signs of adrenal insufficiency (hypoglycemia, lethargy) if maternal use in late gestation. |
| Fertility Effects | No evidence of impaired fertility from animal studies. No human data on fertility effects; theoretical risk of hypothalamic-pituitary-adrenal axis suppression with high systemic absorption, but intranasal route minimizes systemic exposure. |